
CLAIMS

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:

A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R^1;

L^1 and L^2 are each independently absent, C_1-C_6-alkylene, C_1-C_6-heteroalkylene, -O-, -C(O)-, -N(R^3)-, -N(R^3)C(O)-, or -C(O)N(R^3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R^4;

X is N or C;

Y is N, N(R^{5a}), C(R^{5b}), or C(R^{5b})(R^{5c}), wherein the dashed lines representing bonds in the ring comprising X and Y may be single or double bonds as valency permits;

Z is N or C(R^6);

each R^1 is independently hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C_1-C_6 alkylene-aryl, C_1-C_6 alkenylene-aryl, C_1-C_6 alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –OR^A, –NR^BR^C, –$NR^BC(O)R^D$, –NO_2, –$C(O)NR^BR^C$, –$C(O)R^D$, –$C(O)OR^D$, or –$S(O)_xR^D$, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R^7; or

two R^1 groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R^7;

R^2 is absent, hydrogen, or C_1-C_6-alkyl;

each R^3 is independently hydrogen, C_1-C_6-alkyl, or C_1-C_6-haloalkyl;

each R^4 is independently C_1-C_6-alkyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, halo, cyano, oxo, –OR^A, –NR^BR^C, –$C(O)R^D$, or –$C(O)OR^D$;

R^{5a} is hydrogen, C_1-C_6-alkyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl;

each of R^{5b} and R^{5c} is independently hydrogen, C_1-C_6-alkyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, halo, or $-OR^A$;

R^6 is hydrogen, C_1-C_6-alkyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, or halo;

each R^7 is independently C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, $-OR^A$, $-NR^BR^C$, $-NR^BC(O)R^D$, $-NO_2$, $-C(O)NR^BR^C$, $-C(O)R^D$, $-C(O)OR^D$, or $-S(O)_xR^D$, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R^8;

each R^8 is independently C_1-C_6-alkyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or $-OR^A$;

each R^A is independently hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, aryl, heteroaryl, C_1-C_6 alkylene-aryl, C_1-C_6 alkylene-heteroaryl, $-C(O)R^D$, or $-S(O)_xR^D$;

each R^B and R^C is independently hydrogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, cycloalkyl, heterocyclyl, $-OR^A$; or

R^B and R^C together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R^9;




each R^D is independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 heteroalkyl, C_1-C_6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C_1-C_6 alkylene-aryl, or C_1-C_6 alkylene-heteroaryl;








each R^9 is independently C_1-C_6-alkyl or halo; and

x is 0, 1, or 2.





2. The compound of claim 1, wherein A is heterocyclyl or heteroaryl.


3. The compound of any one of claims 1-2, wherein A is a nitrogen-containing heterocyclyl or nitrogen-containing heteroaryl.






4. The compound of any one of claims 1-3, wherein A is selected from , , and , wherein R^1 is as described in claim 1.






5. The compound of claim 4, wherein A is selected from , , , , , , and .

6. The compound of any one of claims 1-3, wherein A is selected from

, , , and , wherein R^1 is as described in claim 1.

7. The compound of claim 6, wherein A is selected from ,




, , , , ,


, , , , and .






8. The compound of any one of claims 1-7, wherein B is heteroaryl or heterocyclyl.



9. The compound of any one of claims 1-8, wherein B is a nitrogen-containing heteroaryl or nitrogen-containing heterocyclyl.


10. The compound of any one of claims 1-9, wherein B selected from selected from




, 
, and 
, wherein R^1 is as described in claim 1.



11. The compound of any one of claims 1-10, wherein B is selected from 
,







, 
, 
, 
, 
,


, and 
.

12. The compound of any one of claims 1-9, wherein B is selected from, 
,


, 
, wherein R^1 is as described in claim 1.

13. The compound of claim 12, wherein B is selected from 
, 
,


. 
, 
, 
, and 
.

14. The compound of any one of the preceding claims, wherein each of L^1 and L^2 is independently absent or C_1-C_6-heteroalkylene (e.g., -$N(CH_3)$-).

15. The compound of any one of the preceding claims, wherein each of L^1 and L^2 is absent.

16. The compound of any one of the preceding claims, wherein X is N.

17. The compound of any one of claims 1-16, wherein X is C.

18. The compound of any one of the preceding claims, wherein Y is $N(R^{5a})$ or $C(R^{5b})$.

19. The compound of any one of the preceding claims, wherein Z is N.

20. The compound of any one of claims 1-18, wherein Z is CH.


21. The compound of any one of claims 1-15, wherein X is C, Y is $N(R^{5a})$, and Z is N.

22. The compound of any one of claims 1-15, wherein X is N, Y is $C(R^{5b})$, and Z is N.

23. The compound of any one of claims 1-15, wherein X is N, Y is $C(R^{5b})$, and Z is $C(R^6)$.

24. The compound of any one of the preceding claims, wherein R^2 is absent.


25. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-a):



(I-a)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L^1, X, Y, R^2, and subvariables thereof are as defined in claim 1.


26. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-b):



(I-b)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L^1, X, Y, R^2, and subvariables thereof are as defined in claim 1.


27. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-c):



(I-c),

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L^1, Z, and subvariables thereof are as defined in claim 1.

28. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-d):




(I-d),

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L^1, Z, and subvariables thereof are as defined in claim 1.

29. The compound of any one of the preceding claims, wherein the compound of Formula (I) is selected from any one of the compounds shown in Table 1 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

30. A compound of Formula (II):



(II)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:

A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R^1;

L^1 and L^2 are each independently absent, C_1-C_6-alkylene, C_1-C_6-heteroalkylene, -O-, -C(O)-, -N(R^3)-, -N(R^3)C(O)-, or -C(O)N(R^3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R^4;

Y is N, C, or C(R^{5b}), wherein the dashed lines representing bonds in the ring comprising Y may be single or double bonds as valency permits;

Z is N or C(R^6);

each R^1 is independently hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C_1-C_6 alkylene-aryl, C_1-C_6 alkenylene-aryl, C_1-C_6 alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –OR^A, –NR^BR^C, –$NR^BC(O)R^D$, –NO_2, –$C(O)NR^BR^C$, –$C(O)R^D$, –$C(O)OR^D$, or –$S(O)_xR^D$, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R^8; or

two R^1 groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R^8;

R^2 is absent, hydrogen, or C_1-C_6-alkyl;

each R^3 is independently hydrogen, C_1-C_6-alkyl, or C_1-C_6-haloalkyl;

each R^4 is independently C_1-C_6-alkyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, halo, cyano, oxo, $-OR^A$, $-NR^BR^C$, $-C(O)R^D$, or $-C(O)OR^D$;

R^{5b} is hydrogen, C_1-C_6-alkyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, halo, or $-OR^A$;

R^6 is hydrogen, C_1-C_6-alkyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, or halo;

R^7 is hydrogen, C_1-C_6-alkyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, halo, or $-OR^A$;

each R^8 is independently C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, $-OR^A$, $-NR^BR^C$, $-NR^BC(O)R^D$, $-NO_2$, $-C(O)NR^BR^C$, $-C(O)R^D$, $-C(O)OR^D$, or $-S(O)_xR^D$, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R^9;

each R^9 is independently C_1-C_6-alkyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or $-OR^A$;

each R^A is independently hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, aryl, heteroaryl, C_1-C_6 alkylene-aryl, C_1-C_6 alkylene-heteroaryl, $-C(O)R^D$, or $-S(O)_xR^D$;

each R^B and R^C is independently hydrogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, cycloalkyl, heterocyclyl, $-OR^A$; or

R^B and R^C together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R^{10};



each R^D is independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 heteroalkyl, C_1-C_6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C_1-C_6 alkylene-aryl, or C_1-C_6 alkylene-heteroaryl;





each R^{10} is independently C_1-C_6-alkyl or halo; and

x is 0, 1, or 2.





31. The compound of claim 30, wherein A is heterocyclyl or heteroaryl.

32. The compound of any one of claims 30-31, wherein A is a nitrogen-containing heterocyclyl or nitrogen-containing heteroaryl.


33. The compound of any one of claims 30-32, wherein A is selected from,  and , wherein R^1 is as described in claim 30.






34. The compound of claim 33, wherein A is selected from , , . and .






35. The compound of any one of claims 30-32, wherein A is selected from


, ,  and .,

wherein R^1 is as described in claim 30.

36. The compound of claim 35, wherein A is selected from ,

, , , , ,

, , , , ,




and

37. The compound of any one of claims 30-36, wherein B is heteroaryl or heterocyclyl.


38. The compound of any one of claims 30-37, wherein B is a nitrogen-containing heteroaryl or nitrogen-containing heterocyclyl.

39. The compound of any one of claims 30-38, wherein B selected from selected from





, and . wherein R^1 is as described in claim 30.

40. The compound of any one of claims 30-39, wherein B is selected from











,





, and .

41. The compound of any one of claims 30-38, wherein B is selected from , , and , wherein R^1 is as described in claim 30.

42. The compound of claim 41, wherein B is selected from , , , , and .

43. The compound of any one of claims 30-42, wherein each of L^1 and L^2 is independently absent or C_1-C_6-heteroalkylene (e.g., -N(CH_3)-).

44. The compound of any one of claims 30-43, wherein each of L^1 and L^2 is independently absent.

45. The compound of any one of claims 30-44, wherein Y is N or C(R^{5b}).


46. The compound of any one of claims 30-45, wherein Z is N.

47. The compound of any one of claims 30-45, wherein Z is CH.

48. The compound of any one of claims 30-47, wherein R^2 is absent.

49. The compound of any one of claims 30-48, wherein R^7 is hydrogen.


50. The compound of any one of claims 30-49, wherein the compound of Formula (II) is a compound of Formula (II-a):



(II-a)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L^1, Z, Y, R^2, R^7, and subvariables thereof are as defined in claim 30.


51. The compound of any one of claims 30-50, wherein the compound of Formula (II) is a compound of Formula (II-b):



(II-b)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L^1, Y, R^2, R^7, and subvariables thereof are as defined in claim 30.


52. The compound of any one of claims 30-51, wherein the compound of Formula (II) is a compound of Formula (II-c):



(II-c)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, Y, R^2, R^7, and subvariables thereof are as defined in claim 30.

53. The compound of any one of claims 30-52, wherein the compound of Formula (II) is a compound of Formula (II-d):



(II-d),

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L^1, Z, R^7, and subvariables thereof are as defined in claim 29.

54. The compound of any one of claims 30-53, wherein the compound of Formula (IV) is selected from any one of the compounds shown in Table 4 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

55. A pharmaceutical composition comprising a compound of any one of claims 1-54 and a pharmaceutically acceptable excipient.

56. The compound of any one of claims 1-54 or the pharmaceutical composition of claim 55, wherein the compound alters a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

57. The compound of any one of claims 1-54 or the pharmaceutical composition of claim 55, wherein the compound binds to a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

58. The compound of any one of claims 1-54 or the pharmaceutical composition of claim 55, wherein the compound stabilizes a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

59. The compound of any one of claims 1-54 or the pharmaceutical composition of claim 55, wherein the compound increases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR.

60. The compound of any one of claims 1-54 or the pharmaceutical composition of claim 55, wherein the compound decreases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR %.

61. A method of modulating splicing of a nucleic acid (e.g., DNA, RNA, e.g., a pre-mRNA) comprising contacting the nucleic acid with a compound of Formula (I) or (II), according to any one of claims 1-54 or the pharmaceutical composition of claim 55.

62. The method of claim 61, wherein the compound increases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR.

63. The method of claim 61, wherein the compound decreases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR.

64. A method of forming a complex comprising a component of a spliceosome (e.g., a major spliceosome component or a minor spliceosome component), a nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA), and a compound of Formula (I) or Formula (II):

comprising contacting the nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA) with a compound of Formula (I) or (II), according to any one of claims 1-54 or the pharmaceutical composition of claim 55.

65. The method of claim 64, wherein the component of a spliceosome is recruited to the nucleic acid in the presence of the compound of Formula (I) or (II).

66. A method of altering the conformation of a nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA) comprising contacting the nucleic acid with a compound of Formula (I) or (II), according to any one of claims 1-54 or the pharmaceutical composition of claim 55.

67. The method of claim 66, wherein the altering comprises forming a bulge in the nucleic acid.

68. The method of claim 66, wherein the altering comprises stabilizing a bulge in the nucleic acid.

69. The method of claim 66, wherein the altering comprises reducing a bulge in the nucleic acid.

70. The method of any one of claims 66-69, wherein the nucleic acid comprises a splice site.

71. A composition for use in treating a disease or disorder in a subject comprising administering to the subject a compound of Formula (I) or (II), according to any one of claims 1-54 or the pharmaceutical composition of claim 55.

72. The composition for use of claim 71, wherein the disease or disorder comprises a proliferative disease (e.g., cancer, a benign neoplasm, or angiogenesis).

73. The composition for use of claim 71, wherein the disease or disorder comprises a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease.

74. The composition for use of claim 71, wherein the disease or disorder comprises neurological disease or disorder.

75. The composition for use of claim 71, wherein the disease or disorder comprises Huntington's disease.

76. A method for treating a disease or disorder in a subject comprising administering to the subject a compound of Formula (I) or (II), according to any one of claims 1-54 or the pharmaceutical composition of claim 55.

77. The method of claim 76, wherein the disease or disorder comprises a proliferative disease (e.g., cancer, a benign neoplasm, or angiogenesis).

78. The method of claim 76, wherein the disease or disorder comprises a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease.

79. The method of claim 76, wherein the disease or disorder comprises neurological disease or disorder.

80. The method of claim 76, wherein the disease or disorder comprises Huntington's disease.